• Study Comparing Paclitaxel, Carboplatin, and Oregovomab with Paclitaxel, Carboplatin, and Placebo for Patients with Advanced Ovarian Cancer

    Not recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Czechia Hungary Italy Spain

  • Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated Drugs:
    Bulgaria Croatia Germany Hungary Italy Lithuania +4

  • Study of Durvalumab with Chemoradiation Therapy for Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Hungary Poland

  • Study on Iberdomide and Dexamethasone, Alone or with Drug Combination, for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Spain

  • Study of drug combination with gemcitabine, cisplatin, carboplatin and avelumab in patients with advanced urothelial cancer to evaluate response to platinum-based chemotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy

  • PET Imaging with 89Zr-Atezolizumab in Patients with Large B-cell Lymphoma Undergoing CD19 CAR T-cell Therapy

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

  • Study on the Effects of Opioid-Free Anesthesia with Ketamine Hydrochloride on Oxygen Levels in Patients Undergoing Bariatric Surgery

    Not recruiting

    4 1 1 1
    Investigated Drugs:
    Spain

  • Study on Murcidencel for Children, Adolescents, and Young Adults with High-Risk Progressive or Recurrent Metastatic Tumors

    Not recruiting

    1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia

  • Study on Psilocybin, Ketamine, and Midazolam for Patients with Treatment-Resistant Depression

    Not recruiting

    2 1 1
    Investigated Drugs:
    Czechia

  • Study on the Safety and Tolerability of Elexacaftor, Tezacaftor, and Ivacaftor in Children with Cystic Fibrosis Aged 12 to Less Than 24 Months

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Denmark Germany The Netherlands

powered by